Victory Pharma (San Diego) has launched the Naprelan Dose Card, an extension of its Naprelan franchise. The Dose Card provides a ten-day tapered dose regimen in a single blister pack. Three days of Naprelan therapy at the maximum daily dose of 1,500 mg (two 750 mg tablets) are followed by a taper to 1,000 mg per day (two 500 mg tabs) for an additional seven days of therapy.
“This product concept is the result of substantial input from our clinical advisors and other members of the pain management community. It was designed to enable healthcare providers to treat pain and inflammation aggressively for a limited period of time, and then taper Naprelan back to a standard dosage strength,” said Mathew Heck, Victory’s CEO.
“The customized dosage regimen in a single prescription product and configuration will aid in patient compliance,” Heck added.
The Dose Card is designed for patients who require relief from mild to moderate pain and inflammation associated with primary dysmenorrhea and acute tendonitis and bursitis. It is also designed for patients suffering from rheumatoid arthritis or osteoarthritis who may be receiving other therapies and need additional anti-inflammatory/analgesic activity for a limited time.